A clinical trial steering committee is finalizing the protocol for a phase III randomized controlled trial evaluating a novel biologic agent for moderate-to-severe plaque psoriasis. During the review, the committee discusses several potential modifications to the study design. Match each proposed trial modification with its most direct and primary impact on the statistical operating characteristics of the study.
- Decreasing the significance level () from 0.05 to 0.01Decreases the probability of a Type I error while increasing the risk of a Type II error
- Expanding the number of study sites to increase total patient enrollmentIncreases statistical power primarily by reducing the standard error of the mean without changing population variance
- Changing the primary endpoint from a continuous clinical score to a rare binary outcomeDecreases statistical power due to loss of data granularity and lower event rates
- Implementing stricter inclusion criteria to create a highly homogenous patient cohortIncreases statistical power by reducing the underlying standard deviation of the outcome measure
Answer
Decreasing alpha alters error risks, increasing sample size reduces standard error, changing to a rare binary endpoint causes power loss, and creating a homogenous cohort reduces population variance.
Each proposed study modification uniquely alters the mathematical components of hypothesis testing. Statistical power is determined by the chosen alpha level, sample size, effect size, and underlying variance. Understanding the specific mechanism of action for each modification is critical for optimizing trial design.
Step-by-Step Solution
Key Concept
The relationship between study design parameters (sample size, variance, alpha threshold, endpoint data type) and statistical power/error rates.